Recombinant Protein Market is Estimated to Witness High Growth Owing to Opportunity of Wide Application Areas Across Healthcare Industry
![]() |
Recombinant Protein Market |
Recombinant
protein products are artificially created proteins produced by various
biological means such as gene cloning and protein engineering. They find wide
application across various therapeutic areas like oncology, hematology,
endocrinology, and others due to their advantages over naturally occurring
proteins for disease treatment. Major therapeutic recombinant proteins
available in the market include insulin, growth hormones, clotting factors,
interferons, interleukins, colony stimulating factors, and others. Some key
features of recombinant proteins include large-scale production, consistency in
quality and purity, precise molecular structure and function, and improved
safety profile.
The global recombinant protein market is estimated to be valued at US$ 3131.37
Mn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market Opportunity:
The wide application areas of recombinant proteins across the healthcare
industry present a major market opportunity. Various diseases like diabetes,
cancer, hemophilia, hepatitis, and others can be effectively managed through
recombinant protein therapeutics. The growing geriatric population globally
which is more prone to chronic diseases will propel the demand for accessible
and effective treatment options like recombinant proteins. Moreover, the
introduction of new recombinant protein drugs in the pipeline and their
approval will further expand the application areas and drive the market growth
over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate. High capital
requirements for R&D and manufacturing pose barriers. However, biologics
and biosimilars have lower entry barriers.
Bargaining power of buyers: The bargaining power of buyers is high due to the
presence of many global players. Buyers can negotiate on price and quality.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as
there are many suppliers for raw materials. However, suppliers of key materials
may exploit their positions.
Threat of new substitutes: The threat of new substitutes is high. Many new
biologics and biosimilars are entering the market as substitutes.
Competitive rivalry: Competition is high amongst existing players due to their
large product portfolios and focus on R&D.
SWOT Analysis
Strength: High demand for therapies to treat cancers and chronic diseases.
Growing biologics market globally.
Weakness: High capital requirements. Stringent regulatory norms. Supply chain
challenges.
Opportunity: Emerging markets growth. Increasing healthcare spending globally.
biosimilars growth.
Threats: Price control regulations. Patent cliffs of major drugs. Reimbursement
issues.
Key Takeaways
The Global
Recombinant Protein Market Share is expected to witness high growth
during the forecast period of 2023 to 2030. The market size for 2024 is
estimated to be US$ 3131.37 Mn, registering a CAGR of 7.3%.
Regional analysis: North America currently dominates the market due to advanced
healthcare infrastructure and high adoption of new therapies. The Asia Pacific
region is expected to grow at the fastest pace owing to growing economies,
increasing healthcare spending, and rising prevalence of chronic diseases.
Key players related content: Key players operating in the recombinant protein
market are Merck KGaA, Allergan plc, Novartis AG, Teva Pharmaceutical
Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski
laboratorij d.d. JGL d.d, Aerie Pharmaceutical and Mylan N.V. Merck KGaA leads
the market with its strong portfolio of recombinant proteins for various
therapies.
For more details on the report, Read-https://www.pressreleasebulletin.com/recombinant-protein-market-trends-size-and-share-analysis/
Comments
Post a Comment